Valuation: Daxor Corporation

Market Cap 52.37M 46.99M 43.44M 39.34M 73.5M 4.99B 74.39M 519M 207M 2.61B 197M 192M 8.29B P/E 2026 *
-42.7x
P/E 2027 * -299x
Enterprise Value 52.37M 46.99M 43.44M 39.34M 73.5M 4.99B 74.39M 519M 207M 2.61B 197M 192M 8.29B EV / Sales 2026 *
5.63x
EV / Sales 2027 * 3.19x
Free-Float
46.7%
Yield 2026 *
-
Yield 2027 * -
1 day-3.47%
1 week-9.01%
Current month-20.98%
1 month-21.67%
3 months-16.53%
6 months-22.96%
Current year-39.73%
1 week 8.76
Extreme 8.76
9.68
1 month 8.76
Extreme 8.76
11.77
Current year 8.56
Extreme 8.56
14.75
1 year 8.56
Extreme 8.56
14.76
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 2012-12-31
Director of Finance/CFO 69 2018-09-27
Chief Tech/Sci/R&D Officer - 2024-06-04
Director TitleAgeSince
Director/Board Member 91 1988-12-31
Chairman 56 2017-02-13
Director/Board Member 70 2016-06-21
Date Insider Type Main position Quantity % Market Cap. Importance
8/28/26 Free

Chief Technology Officer

2,451 0.0420%
6/23/26 Free

Director

2,500 0.0429%
4/8/26 Buy

Chief Executive Officer

1,000 0.0172%
Change 5-day change 1-year change 3-year change Capi.($)
-3.47%-9.01%-31.62%+13.97% 51.9M
+0.33%-1.47%+3.92%+98.07% 14.87B
+0.11%-6.69%+13.10%+123.30% 10.59B
+0.10%+0.47%-20.51%+32.89% 8.83B
+0.13%-3.13%+7.53%+110.17% 6.88B
+0.21%-0.21%-22.10%-10.48% 6.71B
+0.97%+2.53%+1.57%+11.86% 6.59B
-0.64%-1.26%+8.62%+33.05% 4.82B
+0.63%+2.78% - - 3.79B
-0.60%-0.30%-2.07%+8.03% 3.77B
Average -0.22%-1.71%-4.62%+46.76% 6.69B
Weighted average by Cap. +0.19%-1.45%-0.60%+63.54%

Financials

2026 *2027 *
Net sales 9.3M 8.34M 7.71M 6.99M 13.05M 886M 13.21M 92.24M 36.74M 463M 34.9M 34.16M 1.47B 16.4M 14.71M 13.6M 12.32M 23.02M 1.56B 23.3M 163M 64.78M 817M 61.54M 60.24M 2.59B
Net income -1.2M -1.08M -995K -902K -1.68M -114M -1.7M -11.9M -4.74M -59.81M -4.5M -4.41M -190M -200K -179K -166K -150K -281K -19.05M -284K -1.98M -790K -9.97M -751K -735K -31.64M
Net Debt - -
Projected Income Statement - Annual - Daxor Corporation
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
45
Date Price Change Volume
26-10-28 US$8.970 +0.90% 16,219
26-10-27 US$8.890 -3.47% 8,161
26-10-26 US$9.210 -0.43% 9,612
26-10-23 US$9.250 -1.60% 21,054
26-10-22 US$9.400 -3.79% 15,282
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
8.970USD
Average target price
20.00USD
Spread / Average Target
+122.97%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Daxor Corporation